

INTROGEN THERAPEUTICS INC  
 Form 4  
 September 06, 2006

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Aventis Inc.

2. Issuer Name and Ticker or Trading Symbol  
 INTROGEN THERAPEUTICS INC  
 [INGN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
 3711 KENNETT PIKE, SUITE 200  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
 09/01/2006

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 \_\_\_\_ Officer (give title below)  Other (specify below)  
 10% owner and beneficial owner

GREENVILLE, DE 19807

(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common	09/01/2006		S	20,100 D	\$ 3.94 3,757,441	I	SFN <sup>(1)</sup>
Common	09/05/2006		S	13,000 D	\$ 3.99 3,744,441	I	SFN <sup>(2)</sup>
Common	09/06/2006		S	20,439 D	\$ 4.04 3,724,002	I	SFN <sup>(3)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control**

SEC 1474 (9-02)

number.

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned (Instr. 5)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Aventis Inc. 3711 KENNETT PIKE, SUITE 200 GREENVILLE, DE 19807				10% owner and beneficial owner

## Signatures

Kathleen A. Winter,  
President  
09/06/2006  
\*\*Signature of Reporting Person Date

Kathleen A. Winter,  
President  
09/06/2006  
\*\*Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) For Reporting Person Aventis Holdings Inc., reflects ownership of (i) 1,413,720 shares of common stock owned directly by Aventis Holdings inc. and (ii) 2,343,721 shares of common stock by its subsidiary Aventis Pharmaceuticals Inc. For Reporting Person Aventis Inc., reflects ownership of shares owned directly by Aventis Holdings Inc. and Aventis Pharmaceuticals Inc.
- (2) For Reporting Person Aventis Holdings Inc., reflects ownership of (i) 1,400,720 shares of common stock owned directly by Aventis Holdings inc. and (ii) 2,343,721 shares of common stock by its subsidiary Aventis Pharmaceuticals Inc. For Reporting Person Aventis Inc., reflects ownership of shares owned directly by Aventis Holdings Inc. and Aventis Pharmaceuticals Inc.
- (3) For Reporting Person Aventis Holdings Inc., reflects ownership of (i) 1,380,281 shares of common stock owned directly by Aventis Holdings inc. and (ii) 2,343,721 shares of common stock by its subsidiary Aventis Pharmaceuticals Inc. For Reporting Person Aventis Inc., reflects ownership of shares owned directly by Aventis Holdings Inc. and Aventis Pharmaceuticals Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

## Edgar Filing: INTROGEN THERAPEUTICS INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.